Valbenazine: Phase Ib data

The open-label, U.S. Phase Ib T-Force trial in 28 patients ages 6-18 with Tourette’s syndrome showed that once-daily ascending doses of valbenazine for 14 days reduced mean YGTSS score by 31% compared...